Role of KDM6B in Alzheimer’s disease related dementia

KDM6B 在阿尔茨海默病相关痴呆中的作用

基本信息

  • 批准号:
    10739281
  • 负责人:
  • 金额:
    $ 74.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-15 至 2028-04-30
  • 项目状态:
    未结题

项目摘要

Project summary Alzheimer's disease (AD) is a leading cause of dementia characterized by memory and cognitive loss interfering with daily life. Clinical studies showed that the aberrant neuronal activity switch from hyperexcitability at the early stage of disease to hypo-excitability at the late stage is a key feature shared in AD patients. In line with this, levels of the principal excitatory neurotransmitter glutamate and vesicular glutamate transporters (vGluT1/2), the primary mediators of glutamate uptake into synaptic vesicles, were decreased at the late stage of AD patients, which contributed to AD dementia. However, the underlying pathology that leads to glutamate misregulation, aberrant neuronal activity and synaptic dysfunction in AD dementia remains largely unknown. Our recent work identified histone H3K27 demethylase KDM6B as a specific epigenetic regulator of synaptic plasticity and cognitive functions. Conditional knockout of KDM6B in the excitatory neurons reduced presynaptic vesicle numbers, spine density and glutamate release/synaptic activity in mice. Moreover, KDM6B KO mice showed behavioral learning and memory deficits. Importantly, KDM6B expression was reduced in aged brain, while trimethyl lysine 27 on histone H3 (H3K27me3) was increased in brain from late-onset AD patients, which were highly correlated with their cognitive deficits. Tau was required for KDM6B recruitment and regulation in synaptic plasticity and cognitive functions. Tau knockdown interfered with synaptic gene expression. As we know, pathological Tau often occurred in AD and perturbed its physiological functions. These findings led us to hypothesize that epigenetic alteration caused by KDM6B-Tau dysregulation contributes to aberrant neuronal activity switch, cognitive impairment and AD pathogenesis. The goals of this R01 project are to 1) decipher the role of pathological Tau in KDM6B-regulated synaptic activity and 2) determine effects of KDM6B dysregulation on AD pathogenesis in AD mouse models. To ensure the success of the proposed project, we have assembled a strong research team with expertise in AD-related neurodegeneration, epigenetic regulation, and synaptic activity. If successful, this project will reveal the importance of Tau-KDM6B-dependent epigenetic priming in AD pathogenesis and define a new epigenetic mechanism underlying synaptic hyper- and hypo-excitability switch and cognitive impairment in AD, which may provide an innovative therapeutic target and a knowledge foundation on development of a rational strategy to improve cognitive functions in AD patients.
项目概要 阿尔茨海默病 (AD) 是导致痴呆症的主要原因,其特征是记忆力和认知能力丧失 与日常生活。临床研究表明,异常的神经元活动在早期就从过度兴奋转变为 疾病阶段到晚期兴奋性低下是 AD 患者共有的一个关键特征。与此相符, 主要兴奋性神经递质谷氨酸和囊泡谷氨酸转运蛋白 (vGluT1/2) 的水平, 突触小泡摄取谷氨酸的主要介质在 AD 患者晚期减少, 这导致了 AD 痴呆症。然而,导致谷氨酸失调的潜在病理学, AD 痴呆中的异常神经元活动和突触功能障碍仍然很大程度上未知。我们最近的工作 确定组蛋白 H3K27 去甲基化酶 KDM6B 是突触可塑性的特定表观遗传调节因子, 认知功能。兴奋性神经元中 KDM6B 的条件性敲除减少了突触前小泡 小鼠的数量、脊柱密度和谷氨酸释放/突触活动。此外,KDM6B KO 小鼠显示 行为学习和记忆缺陷。重要的是,KDM6B 表达在老年大脑中减少,而 晚发性 AD 患者大脑中组蛋白 H3 (H3K27me3) 上的三甲基赖氨酸 27 增加, 与他们的认知缺陷高度相关。 Tau 是突触中 KDM6B 招募和调节所必需的 可塑性和认知功能。 Tau 蛋白敲低会干扰突触基因表达。据我们所知, 病理性Tau蛋白常出现在AD中并扰乱其生理功能。这些发现使我们发现 假设 KDM6B-Tau 失调引起的表观遗传改变导致神经元异常 活动转换、认知障碍和 AD 发病机制。该 R01 项目的目标是 1) 破译 病理性 Tau 在 KDM6B 调节的突触活动中的作用以及 2) 确定 KDM6B 失调的影响 AD 小鼠模型中 AD 发病机制的研究。为了确保拟议项目的成功,我们聚集了 强大的研究团队,在 AD 相关神经变性、表观遗传调控和突触方面拥有专业知识 活动。如果成功,该项目将揭示 Tau-KDM6B 依赖性表观遗传启动在 AD 中的重要性 发病机制并定义突触高兴奋性和低兴奋性转换背后的新表观遗传机制 AD 中的认知障碍和认知障碍,可能提供创新的治疗目标和知识基础 制定合理的策略来改善 AD 患者的认知功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yingfei Wang其他文献

Yingfei Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yingfei Wang', 18)}}的其他基金

The role of AIF3 in neurodegeneration of Alzheimer's disease
AIF3在阿尔茨海默病神经退行性疾病中的作用
  • 批准号:
    10190767
  • 财政年份:
    2019
  • 资助金额:
    $ 74.95万
  • 项目类别:
The role of AIF3 in neurodegeneration of Alzheimer's disease
AIF3在阿尔茨海默病神经退行性疾病中的作用
  • 批准号:
    10626004
  • 财政年份:
    2019
  • 资助金额:
    $ 74.95万
  • 项目类别:
The role of AIF3 in neurodegeneration of Alzheimer's disease
AIF3在阿尔茨海默病神经退行性疾病中的作用
  • 批准号:
    10434704
  • 财政年份:
    2019
  • 资助金额:
    $ 74.95万
  • 项目类别:
The role of AIF3 in neurodegeneration of Alzheimer's disease
AIF3在阿尔茨海默病神经退行性疾病中的作用
  • 批准号:
    10017857
  • 财政年份:
    2019
  • 资助金额:
    $ 74.95万
  • 项目类别:
PARP-1 Signaling in DNA Damage and Cell Death
DNA 损伤和细胞死亡中的 PARP-1 信号转导
  • 批准号:
    10224826
  • 财政年份:
    2017
  • 资助金额:
    $ 74.95万
  • 项目类别:
PARP-1 Signaling in DNA Damage and Cell Death
DNA 损伤和细胞死亡中的 PARP-1 信号转导
  • 批准号:
    9753761
  • 财政年份:
    2017
  • 资助金额:
    $ 74.95万
  • 项目类别:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
新型 AIF 相关核酸酶 PAAN1 在神经元损伤中的作用
  • 批准号:
    9197695
  • 财政年份:
    2012
  • 资助金额:
    $ 74.95万
  • 项目类别:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
新型 AIF 相关核酸酶 PAAN1 在神经元损伤中的作用
  • 批准号:
    8986742
  • 财政年份:
    2012
  • 资助金额:
    $ 74.95万
  • 项目类别:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
新型 AIF 相关核酸酶 PAAN1 在神经元损伤中的作用
  • 批准号:
    8545914
  • 财政年份:
    2012
  • 资助金额:
    $ 74.95万
  • 项目类别:
The role of a novel AIF-associated nuclease PAAN1 in neuronal injury
新型 AIF 相关核酸酶 PAAN1 在神经元损伤中的作用
  • 批准号:
    8441224
  • 财政年份:
    2012
  • 资助金额:
    $ 74.95万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.95万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了